Enantiomerically pure phosphoindoles as HIV inhibitors
US8486991B2 · kind B2 · utility
0Cited by
26References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 2, 2011 |
| Grant date | Jul 16, 2013 |
| Priority date | — |
| Expiry date | Jun 2, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.